Many of the heart diseases are closely associated with rise in the level of serum lipids, the condition known as 'hyperlipidaemia' which further leads to atherosclerosis. In Ayurvedic view, hyperlipidaemia could be considered analogous with increased dusht medo dhatu in the body which is caused by hypo functioning of medo-dhaatwaghi. According to Sharangdhara, any drug possessing laghu and tikshana properties, katu vipaka and ushana virya performs lekhan karma i.e. curretive and absorptive action on Dosha, Dhatu and Mala. Along with lekhan karma, owing to above said attributes, these drugs improve strength of agni particularly Jathragni and dhaatwagni which further reduces and ultimately stops production of Dhust Medo Dhatu in the body. The Lekhaniya Mahakashaya, mentioned in Charaka Samhita possesses above mentioned characteristics. The only need was to prove its hypolipidaemic effect in human body by conducting clinical trials. The present study proved this fact.
INTRODUCTION
In recent decades, because of the changed lifestyle, daily routine, food habits and environmental changes, the population of unhealthy people is increasing even in developed countries. Increasing work load and mental stress, time shortage and fast life is adding more to health problems. Owing to these factors, many ailments are becoming very common now a-day like hyperlipidaemia, and the related diseases. Major outcome of hyperlipidaemia is atherosclerosis which in the heart causes coronary artery disease (CAD) and ischaemic heart disease (IHD) 1 .
In the past, clinical trials have been done to assess the obesity reducing effect of lekhaniya mahakashaya which is also a result of hypofunctioning of medo dhaatwagni. This research was undertaken to evaluate the changes in the level of serum lipids brought by usage of lekhaniya mahakashaya in clinical dosage.
MATERIAL AND METHODS

Drug profile
Lekhaniya Mahakashaya is the third of the 50 mahakashaya described in fourth chapter of Sutra sthan of Charak Samhita 2 and includes following ten ingredients taken in equal quantity by weight:
Quality control and standardization of drug All the contents of the drug were procured by pharmacy department of the college and evaluated for quality and standardization on the basis of following parameters-(a) Organoleptic or morphological evaluation -Shape, colour, odour, taste, size and other special features. 
Formulations of the drug
Following two pharmaceutical preparations of lekhaniya mahakashaya were prepared for the clinical trials:-i) Decoction form -The mixture of all the ten contents of drug formulation was turned into Yavkoot choorna (crude powder) for the preparation of decoction. ii) Extract form -Extract of each constituent of drug formulation was extracted out separately using suitable method at Amsar Pharmacy Pvt. Ltd, Indore, M.P., India
Dosage
Dosage of decoction of formulation
According to Sharangdhara Samhita, dosage of decoction formulation of any drug is as follows 3 -(i) 4 taula i.e. 40 ml (Heen matra or low dosage) (ii) 6 taula i.e. 60 ml (Madhyma matra or medium dosage) (iii) 8 taula i.e. 80 ml (Uttam matra or high dosage) Now a days, the physical and mental strengths of the people are not strong enough to tolerate the high dosage i.e. uttam matra of any ushana and tikshana drug like Lekhaniya Mahakashaya. So, it was planned to use only low and medium dosage of the drug for clinical trials.
Dosage of extract formulation
According to Sharangdhara, dosage of choorna (powder) form of any drug is 3 to 6 gm or in other words, the dosage range is 4.5 + 1.5 gm under this research work, average of this range i.e. 4.5 gm was chosen to calculate the dosage of extract formulation. If 4.5 gm of powder of drug formulation is planned to be given to each patient, twice a day for a month, then 270 gm of Lekhaniya Mahakashaya would be required for each patient. For 15 patients, 4050 gm of medicine would be required. In other words, each of the content of formulation is required in quantity of 405 gm. So, 405 gm of each of the contents of formulation were extracted out separately to prepare its extract formulation. The dosage range of choorna formulation is 4.5 + 1.5 gm. So, the equivalent dosage of extract formulation came out to be 820 + 274 mg or in other wordsHigh dosage = 820 + 274 = 1094 mg Medium dosage = 820 mg Low dosage = 820 -274 = 546 mg In the present study, low and medium dosage of extract formulation of the drug was used for clinical trials for the same reason as mentioned in the case of decoction formulation. Depending upon the type of formulation planned to be given, these patients were divided randomly into two groups entitled F 1 and F 2 each containing 15 patients. Each group was further divided into two subgroups on the basis of dosage of the formulation planned to be given to the patients as followsa) Sub-group F 1 LD -To be treated with heen matra i.e. 40 ml of decoction of Lekhaniya Mahakashaya. b) Sub-group F 1 MD -To be treated with madhyam matra i.e. 60 ml of decoction. c) Sub-group F 2 LD -To be treated with heen matra i.e.
Selection of patients
546 mg of extract of Lekhaniya Mahakashaya. d) Sub-group F 2 MD -To be treated with madhyam matra i.e. 820 mg of extract. Pre-medication estimation of serum lipid profile of the patients Before starting medication, blood sample of each patient was taken for the biochemical assay of their serum lipid profiles. Purpose of this pre-medication blood sampling and lipid profile assay was two foldsi) To confirm the hyperlipidaemic status of the patients before clinical trials. ii) To compare this lipid profile with post medication lipid profile of the patients to ascertain the effects of lekhaniya mahakashaya on their lipid profile.
Medication of the patients
The medication plan for the patients of different subgroups was designed as mentioned belowa) Patients of sub-group F 1 LD were given 40 ml of decoction of lekhaniya mahakashaya, 12 hourly i.e. twice a day for one month. b) Patients of sub-group F 1 MD were given 60 ml of decoction of lekhaniya mahakashaya, 12 hourly for one month. c) Patients of sub-group F 2 LD were given 546 mg of extract of lekhaniya mahakashaya, 12 hourly for one month. d) Patient of sub-group F 2 MD were given 820 mg of the extract of lekhaniya mahakashaya, 12 hourly for one month. Post-medication estimation of serum lipid profile of the patients After completion of medication for one month, blood sample of each patient was taken and serum lipid profile assay was done for the comparative study of it with premedication lipid profile.
Criteria for overall assessment
Comparative analysis of the pre-medication and postmedication serum lipid profile of each patient was the sole criteria to assess the effect of different formulations of lekhaniya mahakashaya on their lipid profiles.
RESULTS
Sub-group F 1 LD -
The results showed an average decrease of 21.1% in the level of serum triglycerides, an average decrease of 10.78% in the level of serum cholesterol, an average decrease of 21.27% in the level of serum very low density lipids (VLDL), an average decrease of 30.24% in the level of serum low density lipids (LDL) and an average decrease of 21.37% in the level of serum total lipids in the patients of this subgroup. Almost no change was found in level of serum high density lipids (HDL). Sub-group F 1 MD -In these patients, an average decrease of 22.57% in the level of serum triglycerides, an average decrease of 20.87% in the level of serum cholesterol, an average decrease of 22.83% in the level of serum very low density lipids, an average decrease of 26.11% in the level of serum low density lipids and an average decrease of 18.02% in the level of serum total lipids was found. But, an average increase of 5.65% was found in level of serum high density lipids. Sub-group F 2 LD -In these patients, an average decrease of 27.04% in the level of serum triglycerides, an average decrease of 21.86% in the level of serum cholesterol, an average decrease of 26.7% in the level of serum very low density lipids, an average decrease of 26.52% in the level of serum low density lipids and an average decrease of 20.31% was found in the level of serum total lipids. But, an average increase of 5.41% was found in level of serum high density lipids. Sub-group F 2 MD -In these patients, an average decrease of 27.94% in the level of serum triglycerides, an average decrease of 24.98 in the level of serum cholesterol, an average decrease of 27.93% in the level of serum very low density lipids, an average decrease of 33.26% in the level of serum low density lipids and an average decrease of 23.07% was found in the level of serum total lipids. An average increase of 14.14% was also found in level of serum high density lipids.
DISCUSSION
Comparative study of results shows that the patients of sub-group F 2 MD which were treated with 820 mg of extract, twice a day for one month, got maximum benefit among four sub-groups. Patients of sub-group F 1 LD which were treated with 40 ml of decoction formulation, twice a day for one month, got least benefit among four sub-groups. It was also proved that extract formulation yields better hypolipidaemic effect than decoction formulation. The madhyam matra (medium dose) of decoction as well as extract formulation yields better hypolipidaemic effect than Heen matra (low dose). It was found that Lekhaniya Mahakashaya has got maximum depleting effect on serum low density lipids. 
Probable mode of action from Ayurvedic point of view
Hyperlipidaemia is caused by hypo-functioning of 'Medodhaatwagni'. As a result of this condition, 'dushta medodhaatu' i.e. unwanted quantity of lipids is increased in the body.
As per Sushruta, the drugs which perform lekhan karma are mainly constituted of Vayu and Agni mahabhoot 4 . Hence, the properties of wholesome formulation of Lakhaniya Mahakashaya are as followsRasa -Katu, Tikta Vipaka -Katu Virya -Ushna Guna -Laghu, Tikshana, Ruksha All these properties of Lakhaniya Mahakashaya render it a Medo-dhaatu depleting formulation, because, these properties are contrary to the properties of Medo-dhaatu 5 . Secondly these properties of Lakhaniya Mahakashaya, make it a 'jatharaagni' promoting formulation. Jatharaaghi stimulation corrects hypofunctioning of Medo-dhaatwagni and checks increase in the quantity and subsequent deposition of Medo-dhaatu in the body. Relevant actions of Lakhaniya Mahakashaya because of each one of these properties are as follows:-Laghu guna is characteristic of drugs constituted of 'Vaayu and Agni mahabhoota'. Drugs, possessing this property produce lightness in the body and promote the jatharaagni. Both of these actions help in reducing accumulation of medo dhaatu in the body. Tikshna guna is characteristic of drugs, constituted of Agni mahabhoota. These drugs perform action of shodhana, lekhana and kapha-hara karma. Owing to the above mentioned properties, Lekhaniya Mahakashaya is igneous in nature, stimulates jatharaagni and performs lekhan karma in the body. When we look at characteristics and actions of contents of Lekhaniya Mahakashaya individually, we find each of the contents contribute to lekhan karma. Katuka is 'pitta rechaka and pitta virechana' (choleretic and cholagogue purgative drug). This drug excretes pitta (bile) which is required for the 'ahaar paaka'. This results into depletion of dhaatu, mainly Medo and Mans dhaatu. By inducing virechana, it performs shodhan karma reducing medodhaatu in the body 6 . Haridra and Daruharidra stimulate agni and performs lekhana karma because of their katutikta taste, katu vipaka, ushna virya and laghu, ruksha guna. Tikshana guna of Vacha, Chitraka and Kushtha 7 along with above mentioned characteristics aids more to lekhan karma. Chirbilva and Haimvati mainly perform lekhan karma on dhaatu and body because of their properties. Contrary to other contents of Lekhaniya Mahakashaya, Mustak and Ativisha performs 'grahi' karma hence, they check the excessive motions caused by Katuka. Grahi karma, also helps re-absorption of water in large intestine reducing the risk of patient getting dehydrated because of loose motions. So, it is concluded that each of the content of the Lekhaniya Mahakashaya contributes to make it an ideal hypolipidaemic formulation.
CONCLUSION
Lekhaniya Mahakashaya has got hypolipidaemic effect and the most probable mode of action is by excreting bile in faeces reducing absorption of all types including fats lipids in the gut. In comparison to the decoction formulation, the extract formulation of Lekhaniya Mahakashaya yields better hypolipidaemic effect and the madhyam matra of extract or decoction formulation yields better hypolipidaemic effect than Heen matra of respective form. Further, it was concluded that Lekhaniya Mahakashaya has got maximum effect on low density lipids and least on high density lipids. At the same time, it was concluded that more precise clinical trials should be taken to ascertain the exact details of pharmacological action of Lekhaniya Mahakashaya on serum lipids and lipoproteins before recommending it as an established hypolipidaemic formulation.
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